Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Covagen AG
Zurich, Zurich canton, Switzerland
- Ownership
- Private
- Employees
- ~23
- Development stage
- Other
01
Overview
Covagen developed a proprietary platform for generating bispecific and multispecific protein therapeutics called FynomAbs by fusing human Fynomer binding proteins to antibodies. Their lead candidate COVA322 entered Phase 1b clinical trials for psoriasis and targeted both TNF-alpha and IL‑17A. Other programs included preclinical assets in oncology and autoimmune disease. The company was acquired by Cilag GmbH International (Janssen/Johnson & Johnson) in August 2014; development of some programs has since been discontinued or integrated into the parent pipeline.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Bispecific antibodies (FynomAbs)fusion proteinsprotein therapeutics
- Industry
- Biotech
02
Partnerships
Investors included Novartis Venture Fund, Edmond de Rothschild Investment Partners; acquired by Cilag/Janssen/J&J which became the key partner/owner post-acquisition
Beyond the preview
Go deeper on Covagen AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Covagen AG.